Strategic partnerships Tilak has established international partnerships with Novartis and distribution ambitions in Europe and the US, presenting a pathway for scalable oculo-digital therapeutics collaborations and white-label opportunities with pharma and healthcare providers.

Funding momentum Recent multi-million funding rounds (10.6M EUR in 2023, 7-8M EUR in 2021) indicate strong investor confidence and potential for accelerated expansion, making it a favorable time to approach for enterprise deployments, scale partnerships, and co-development deals.

Regulatory readiness OdySight is CE-marked and deployed in multiple languages with healthcare system support in France, suggesting a credible regulatory posture and a replicable path to enter additional markets via health system reimbursements and physician-led adoption.

Clinical adoption With 15,000 patients prescribed in France since 2018 and a model combining medical expertise with gamified engagement, there is a clear user base and clinical validation that can be leveraged to expand hospital networks, clinics, and remote monitoring programs.

Growth-ready tech A modern tech stack (Kubernetes, PostgreSQL, MongoDB, Node.js, PHP, Symfony) supports scalable SaaS deployment and data analytics for outcomes measurement, enabling upsell of advanced patient monitoring features, data integration with EMRs, and enterprise-grade security to attract large health systems.